Literature DB >> 26909004

Companies Take Aim at MRSA Infections.

Chris Fellner.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most widespread and virulent nosocomial pathogens. The late-stage clinical pipeline includes an array of proposed new treatments aimed at MRSA-related skin infections and pneumonia.

Entities:  

Year:  2016        PMID： 26909004      PMCID： PMC4745641     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  5 in total

Review 1.  Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.

Authors:  Keith A Rodvold; Kevin W McConeghy
Journal:  Clin Infect Dis       Date:  2014-01       Impact factor: 9.079

Review 2.  New drugs for methicillin-resistant Staphylococcus aureus: an update.

Authors:  Krishan Kumar; Sidharth Chopra
Journal:  J Antimicrob Chemother       Date:  2013-02-20       Impact factor: 5.790

Review 3.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 4.  Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods.

Authors:  Stefania Stefani; Doo Ryeon Chung; Jodi A Lindsay; Alex W Friedrich; Angela M Kearns; Henrik Westh; Fiona M Mackenzie
Journal:  Int J Antimicrob Agents       Date:  2012-01-09       Impact factor: 5.283

5.  National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011.

Authors:  Raymund Dantes; Yi Mu; Ruth Belflower; Deborah Aragon; Ghinwa Dumyati; Lee H Harrison; Fernanda C Lessa; Ruth Lynfield; Joelle Nadle; Susan Petit; Susan M Ray; William Schaffner; John Townes; Scott Fridkin
Journal:  JAMA Intern Med       Date:  2013-11-25       Impact factor: 21.873
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.